Editor's note: Find the latest COVID-19 news and guidance in Medscape's Coronavirus Resource Center.

More than a third of people with COVID-19 symptoms said they were not feeling back to their normal state of health when researchers called them a couple weeks after testing, according to a recent CDC report.

The US has officially tallied more than 5 million confirmed cases of COVID-19, 1.5% of the country's population.

Moncef Slaoui, PhD, the chief of the federal government's effort to develop COVID-19 vaccines and therapeutics quickly, dubbed "Operation Warp Speed," said the program's previously stated goal to deliver 300 million vaccine doses by January 2021 would likely not fully occur until the middle of the year, depending on the data from clinical trials.

The program aims to deliver 300 million courses of therapy, not individual doses, as some vaccines will likely require two doses, he clarified, speaking to a National Academies of Sciences, Engineering, and Medicine committee that will issue recommendations on COVID-19 vaccine allocation in September.

Slaoui also said that every vaccine candidate would seek full approval from the US Food and Drug Administration (FDA), as opposed to an emergency use authorization, which has been used for most of the COVID-19 diagnostics and therapeutics that have been brought to the US market so far.

Slaoui said that Operation Warp Speed had an agreement with the FDA to quickly review data, but that approval criteria "will be the same as those used for any regular vaccine.".

Although there are already guidelines that address inpatient management of steroid-induced hyperglycemia, the UK National Diabetes COVID-19 Response Group has put out new guidance addressing glucose management particularly for COVID-19 patients receiving dexamethasone therapy.